Novavax Inc. announced the completion of the U.S. marketing authorization transfer for its COVID-19 vaccine, Nuvaxovid™, to Sanofi. This transfer fulfills part of the collaboration and license agreement between the companies and triggered a $25 million milestone payment to Novavax. Along with the earlier European Union transfer, Novavax has secured a total of $225 million in milestone revenue to date in 2025. Under the agreement, Novavax remains eligible for additional future milestones and royalties related to Nuvaxovid, combination products developed by Sanofi using Nuvaxovid, and new vaccines created by Sanofi utilizing Novavax's Matrix-M® adjuvant.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novavax Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-105818), on November 04, 2025, and is solely responsible for the information contained therein.